Subgroup analysis of PEARLS/KEYNOTE-091 Study
Results from the PEARLS/KEYNOTE-091 study, a triple-blind phase 3 trial, have shown that pembrolizumab significantly improved disease-free survival in patients with completely resected stage IB-IIIA, regardless of whether they had prior adjuvant chemotherapy. Dr. Kersti Oselin from North Estonia Medical Centre, Tallinn, presented at ASCO 2023 the outcomes for patients who had received 1-4 cycles of prior adjuvant chemotherapy.
With the educational support of:
